NCT07518589 is a Phase 1 clinical trial of CMS-D008 in Evaluate the Safety and Tolerability, sponsored by Shenzhen Kangzhe Biotechnology Co., Ltd..

Who is sponsoring NCT07518589?

NCT07518589 is sponsored by Shenzhen Kangzhe Biotechnology Co., Ltd..

What drugs are being tested in NCT07518589?

Interventions in NCT07518589: CMS-D008, Placebo.

What condition does NCT07518589 study?

NCT07518589 studies Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants.

Is NCT07518589 still recruiting?

NCT07518589 is currently not yet recruiting. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT07518589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults

Not yet recruiting Phase 1 Last updated 8 April 2026

What this trial tests

Phase 1 trial testing CMS-D008 in Evaluate the Safety and Tolerability in 110 participants. Not yet recruiting.

Timeline

2 April 2026

Primary endpoint
24 November 2027

10 December 2027

Quick facts

Lead sponsor	Shenzhen Kangzhe Biotechnology Co., Ltd.
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	110
Start date	2 April 2026
Primary completion	24 November 2027
Estimated completion	10 December 2027

Drugs / interventions tested

CMS-D008
Placebo

Conditions studied

Evaluate the Safety and Tolerability — all drugs for Evaluate the Safety and Tolerability →
Healthy and Overweight or Obese Participants — all drugs for Healthy and Overweight or Obese Participants →

Sponsor

Shenzhen Kangzhe Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 55, any sex, with Evaluate the Safety and Tolerability or Healthy and Overweight or Obese Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as Part-1 SAD study), Part-2 Multiple Ascending Dose (MAD) study (hereinafter referred to as Part-2 MAD study), and Part-3 expansion study. The study aims to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and immunogenicity of single and multiple subcutaneous injections of CMS-D008 injection in Chinese healthy and overweight or obese adult participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shenzhen Kangzhe Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT07402369 — Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07518589 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Kangzhe Biotechnology Co., Ltd.
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07518589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing